UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
Exhibit Number
|
Description
|
99.1
|
24
April 2024 - “Appointment of Dawn Allen as
CFO”
|
99.1
Haleon plc: Appointment of Dawn Allen as Chief Financial
Officer
24 April 2024: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE:
HLN) today
announces the appointment of Dawn Allen as Chief Financial Officer
("CFO"). Dawn will join Haleon on 28 October 2024 and will assume
the role of CFO and join the Board from 1 November
2024.
This appointment follows Tobias Hestler informing the Board of his
decision to step down from his position as CFO to better balance
work demands with the management of a long-term health condition.
Tobias will step down from the Board on 1 November 2024 and will
remain within the business until the end of the year in order to
ensure an orderly transition.
Dawn is currently the CFO at Tate & Lyle plc. Prior to joining
Tate & Lyle, Dawn had a 25-year career at Mars Inc., where she
was most recently Global CFO and VP Global Transformation. Before
that, she held a number of senior financial roles in Europe and the
US. Dawn also currently serves as a Non-Executive Director and
member of the Audit and Risk Committee of ITV plc.
Brian McNamara, Haleon's Chief Executive Officer
commented: "We
are delighted to have appointed Dawn as our next CFO. She has a
proven track record as a CFO with extensive consumer and
international experience and will be a great addition to our
executive team. I want to take this opportunity to thank Tobias for
his significant contribution in creating Haleon as a standalone
business and for the close partnership over the last few years. He
has played a critical role in shaping and building Haleon's
foundations and putting us on a path for long-term
success."
Sir Dave Lewis, Haleon's Chair commented: "On
behalf of the Board, I would like to thank Tobias for his
significant input to the Board and his strong support to Brian and
the management team and wish him all the very best for the future.
We are very pleased to appoint Dawn as Haleon's CFO. Dawn has deep
consumer and financial experience and will be a very welcome
addition to the Board."
Dawn Allen commented: "I
am very excited to join the team at Haleon. Its clear purpose and
fascinating journey through separation and beyond sets a strong
foundation for the future. I am looking forward to help shape the
next phase of the journey."
Tobias Hestler commented: "I
have been a Type 1 diabetic all my life and it's a condition that
has always needed careful management. That becomes even more
important as you get older and I've therefore concluded that after
30 years, now is the right time to step down and take my experience
into non-executive and advisory roles. I've had 15 fantastic years
helping bring together the businesses that Haleon has become and
listing the company. I'm very proud of the business we have built
and the potential that it has. I will continue at Haleon until the
end of this year and look forward to helping ensure an orderly
transition to Dawn as she takes on the role."
Haleon also separately announces today the appointment of Line De
Decker as Chief Human Resources Officer. With over 27 years'
experience, Line is currently Chief People & Sustainability
Officer at Aliaxis. Prior to that, she held roles at GSK and
DuPont, having started her career at PWC. Line will join Haleon on
1 August 2024.
Enquiries
|
|
|
|
Investors
|
Media
|
Sonya Ghobrial
|
+44 7392 784784
|
Zoë Bird
|
+44 7736 746167
|
Rakesh Patel
|
+44 7552 484646
|
Nidaa Lone
|
+44 7841 400607
|
Emma White
|
+44 7792 750133
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
|
|
Notes to Editors
Biography
Dawn Allen
Dawn Allen
started her career in 1991 working for the auditing firm EY based
in the UK. In 1995, she joined Courtaulds plc in their
Corporate Finance department before moving to Mars Inc., in 1997
initially to work as Europe Confectionary Finance Manager spending
some time based in the Netherlands. She returned to
the UK in 2000 taking on Sales Finance and Financial
Controller roles before being appointed as Country CFO Mars
Chocolate UK in 2007.
In 2013 she moved to the USA to act as Regional CFO
Wrigley Americas before moving back to London in 2016 to
take on the role of Global Divisional CFO, Food, Drinks and
Multisales. Then, in 2020, she was appointed as Global CFO &
VP, Global Transformation at Mars. In May 2022, Dawn was
appointed CFO of Tate & Lyle plc.
Dawn was appointed as a Non-Executive Director and member of the
Audit & Risk Committee of ITV plc in October
2023. Dawn
was previously a Non-Executive Director of Tasty Bite Eatables Ltd,
a public company based in India. She holds a Bachelor of
Science in Chemistry at Bath University, UK, and is a member
of the Institute of Chartered Accountants
of England and Wales.
There is no further information to be disclosed in respect of
paragraph 9.6.13R of the UK Listing Rules.
Remuneration Statement
Dawn Allen
Dawn's remuneration arrangements
on appointment have been set in accordance with the Haleon
Directors' Remuneration Policy approved by shareholders at the 2023
AGM on 20 April 2023 and will include:
●
|
Annual
salary of £730,000;
|
●
|
Benefits
and pension contributions in line with the Directors' Remuneration
Policy (and aligned with the majority of the wider UK
workforce);
|
●
|
Provisions
relating to annual bonus and long-term incentive plans: a maximum
AIP opportunity of 200% of annual salary and a maximum PSP award of
350% of annual salary; and
|
●
|
A
pro-rated 2024 PSP award to reflect her start date of 28 October
2024.
|
All incentive awards are subject to malus and clawback
provisions.
Dawn will receive replacement awards to compensate the loss of
incentive payments from her current employment. These awards remain
subject to performance conditions where appropriate and will
mirror, as closely as possible, the value, terms and release
timeline of the forfeited awards.
Tobias Hestler
As required by
section 430(2B) of the Companies Act 2006, details of remuneration
payments made or to be made to Tobias on stepping down as a
Director of the Company are detailed below.
Tobias's remuneration arrangements in respect of his departure have
been determined by the Remuneration Committee in line with the
Directors' Remuneration Policy.
Tobias will continue to receive his salary, pension and benefits
until he leaves the business on 31 December 2024. Thereafter, he
will be paid in lieu of notice for the remainder of his 12-month
notice period until 23 April 2025. A capped contribution will be
made to legal fees.
He will be considered an eligible leaver and, in accordance with
the Directors' Remuneration Policy, will be eligible for a 2024
annual incentive award to be determined by the Remuneration
Committee in February 2025 and paid in March 2025, with 50%
deferred for three years.
Outstanding deferred bonus awards will be released on the original
timetable, subject to malus and clawback provisions.
Outstanding long-term incentive awards will be pro-rated to the end
of Tobias's employment and will vest in line with the original
vesting dates, subject to satisfaction of the performance
conditions.
All outstanding awards will remain subject to malus and clawback
provisions. His 2024 PSP award which was granted in March 2024 will
lapse.
Tobias's shareholding will be subject to the share ownership
guideline (350% of his current salary or, if lower, his
shareholding at the time of termination) for a period of two years
after the termination of his employment.
Full remuneration arrangements for the outgoing and the incoming
CFO will be disclosed in the Annual Report and Form-20F 2024 and
subsequent years as appropriate.
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health,
with a purpose to deliver better everyday health with humanity.
Haleon's product portfolio spans five major categories - Oral
Health, Pain Relief, Respiratory Health, Digestive Health and
Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren,
Theraflu, Otrivin, Polident, parodontax and Centrum - are built on
trusted science, innovation and deep human
understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
HALEON PLC
(Registrant)
|
Date: April 24, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
Name:
|
Amanda
Mellor
|
|
|
Title:
|
Company
Secretary
|